AZD6234_Dosage, benefits & legal status
Corrected November 14, 2026: receptor selectivity and 1 earlier
Also known as lenbelintide, the drug name on AstraZeneca's three phase 3 SELENE trial records at ClinicalTrials.gov since September 2026 and a WHO recommended international nonproprietary name since March 2026.
An experimental weekly fullness-hormone shot from AstraZeneca, built to act like natural amylin.
What is AZD6234?
Plain language first. The technical label stays, but it never stands alone.Overview
What it's used for
An experimental weekly shot that copies a natural fullness hormone to reduce appetite.
How does AZD6234 work?
What it does in the body, and where.AZD6234 is a long-acting amylin analog. AstraZeneca calls it a selective amylin receptor agonist; the WHO entry that names it lenbelintide calls it a dual amylin and calcitonin receptor agonist. The measured numbers explain why both labels are in use.
- 01It works through amylin receptorsFullness signaled through the brainstem rather than the gut-hormone route.
- 02How selective it isIn AstraZeneca's cell assays, presented at EASD in September 2024, AZD6234's potency at the amylin-3 receptor relative to the calcitonin receptor was 1.6 in human cells and 0.9 in rat cells, a profile the authors describe as matching pramlintide and mimicking native amylin. A ratio that close to 1 means it activates both receptors at close to equal potency. "Selective" in AstraZeneca's usage means it does not favor the calcitonin receptor the way the DACRA compounds do. WHO's naming entry from July 2025 classes it as a dual amylin/calcitonin receptor agonist, and the same numbers fit that label. Of the two, the bare word "selective" is the weaker description, because a ratio near 1 is not what most readers picture when they read it. An earlier version of this page gave the ratio as roughly 14; that was a misreading of the abstract's experiment count.
- 03Still investigationalThree phase 3 trials were recruiting as of November 2026. No approval anywhere.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, positioned by AstraZeneca as a selective amylin-receptor optionInvestigational
The published record
Papers about AZD6234 · this compound only
Searched: AZD6234, lenbelintide.
18 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
16 registered trials · none with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

At a glance
Four things to know about AZD6234
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
About 4 days
How much, and do you cycle it?
The range, and whether you take breaks.Once weekly in trials; milligram dose levels have not been publicly disclosed, weekly. Not cycled in the trials Trial dose
Given continuously for the whole study period, with the dose stepped up at the start, which is a ramp rather than a cycle.
About 4 daysTrial protocol
Reported in a peer-reviewed review rather than in a primary pharmacokinetic paper: the review describes dose-proportional pharmacokinetics in the phase 1 single ascending dose study and a terminal half-life of approximately 4 days, which is what supports once-weekly dosing. The review was read in a reproduction of its PDF, because the publisher's own copy is not reachable from here. AstraZeneca has published no pharmacokinetic paper of its own, and the trial's own results are not posted.
Source: Alhazmi and le Roux, Amylin analogs: the next major class of weight loss therapy, Diabetes, Obesity and Metabolism 2026, reporting the phase 1 single ascending dose study (NCT05511025)
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
AZD6234 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 16% charged residues, 41% hydrophobic. Acid may help.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Pregnancy or breastfeeding
- Any prescription medicine you take regularly, without checking for interactions first
- Anyone who wants established safety data, because none exists for this compound in humans
Stop and get help
- Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
- Redness, heat, or pus at the injection site, which can signal infection
- Any severe or unexpected symptom
- Anything unusual, since there is no known safety profile to compare it against
Common effects
- Stomach side effects.
- Trial-only.
- Redness, soreness, or a small bump at the injection site
- Beyond the above, unknown. There is no reliable human data on what this compound commonly causes
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is AZD6234 approved?
And where the numbers on this page come from.No. AZD6234 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked14 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesClinicalTrials.gov, AZD6234 phase 1 single-ascending-dose study (NCT05511025)Frontiers in Endocrinology, obesity pipeline reviewRauschecker et al., Obesity (ObesityWeek abstract)ClinicalTrials.gov, ARAY phase 2 (NCT06851858)ClinicalTrials.gov, ASCEND phase 2b (NCT06862791)ClinicalTrials.gov, CONTEMPO phase 1/2 (NCT06151964)ClinicalTrials.gov, SELENE 2 phase 3 (NCT07784270)ClinicalTrials.gov, AZD6234 phase 1 renal impairment study (NCT06845813)ClinicalTrials.gov, AZD6234 phase 1 relative bioavailability study (NCT07220954)ClinicalTrials.gov, SELENE 3, AZD6234 as an adjunct to incretin-based therapies (NCT07776509)ClinicalTrials.gov, SELENE 2, AZD6234 in type 2 diabetes with obesity or overweight (NCT07784270)ClinicalTrials.gov, SELENE 1, AZD6234 in obesity or overweight without type 2 diabetes (NCT07784725)WHO Drug Information, Proposed INN List 133WHO Drug Information, Recommended INN List 95Hornigold et al., EASD 2024 abstract 707, Characterisation of AZD6234 in rodent models of weight loss and aversion (Diabetologia 67, Suppl 1)AstraZeneca, Meet the Management: Weight Management investor presentation, November 4, 2024Alhazmi and le Roux, Amylin analogs: the next major class of weight loss therapy, Diabetes, Obesity and Metabolism
What has happened recently
Still in trials. Three phase 3 trials (SELENE 1, 2 and 3) were recruiting as of November 2026, under the name lenbelintide. It is not approved anywhere and long-term safety is unknown.
You can compare this against the whole library, or read how to check a seller.
What else is like AZD6234?
Others in Amylin analogs, side by side.If you're weighing AZD6234, it's worth reading NN9662 (Triple), PF-08653945 (MET-233i), and Pramlintide in the same class. See all four compared side by side.
An experimental weekly fullness-hormone shot from AstraZeneca, built to act like natural amylin.
- Dose
- Once weekly in trials; milligram dose levels have not been publicly disclosed
- How often
- Weekly
Novo's other triple agonist, the one that hits amylin.
- Dose
- No dose disclosed in any trial record
- How often
- Once weekly
An experimental amylin shot designed for monthly dosing, now in a 940-person phase 2b.
- Dose
- 0.15 up to 1.2 mg weekly (phase 1 doses)
- How often
- Weekly; monthly dosing under test
An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger.
- Dose
- 0.015 up to 0.12 mg per dose (start low, increase slowly)
- How often
- With meals
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- ClinicalTrials.gov, AZD6234 phase 1 single-ascending-dose study (NCT05511025)(2024)Phase 1 randomized, single-blind, placebo-controlled study of AZD6234 in overweight or obese adults; 54 participants, completed December 2023.
- Frontiers in Endocrinology, obesity pipeline review(2025)Reports the single-ascending-dose study of AZD6234: single subcutaneous doses of 0.3, 0.9, 1.5, 2.7, 3.0, and 4.2 mg were studied. No weekly dose schedule has been published.
- Rauschecker et al., Obesity (ObesityWeek abstract)(2024)Abstract reporting safety, tolerability, and pharmacokinetics of AZD6234 from the single-ascending-dose study.
- ClinicalTrials.gov, ARAY phase 2 (NCT06851858)Phase 2 study of AZD6234 added to a stable GLP-1 medicine in type 2 diabetes. Active, not recruiting.
- ClinicalTrials.gov, ASCEND phase 2b (NCT06862791)Phase 2b study of AZD6234 with AZD9550; 377 participants. Active, not recruiting.
- ClinicalTrials.gov, CONTEMPO phase 1/2 (NCT06151964)Phase 1/2 study of AZD6234. Active, not recruiting.
- ClinicalTrials.gov, SELENE 2 phase 3 (NCT07784270)Phase III, randomized, double-blind, placebo-controlled study (D8750C00012) in participants with type 2 diabetes and obesity or overweight. Not yet recruiting.
- ClinicalTrials.gov, AZD6234 phase 1 renal impairment study (NCT06845813)Phase 1 study of AZD6234 in renal impairment. Completed.
- ClinicalTrials.gov, AZD6234 phase 1 relative bioavailability study (NCT07220954)Phase 1 relative bioavailability study of AZD6234. Not yet recruiting.
- ClinicalTrials.gov, SELENE 3, AZD6234 as an adjunct to incretin-based therapies (NCT07776509)(2026)Phase 3, recruiting, 500 participants planned. Intervention listed as Drug: Lenbelintide, other name AZD6234, from the record version submitted September 23, 2026; the first version listed Drug: AZD6234.
- ClinicalTrials.gov, SELENE 2, AZD6234 in type 2 diabetes with obesity or overweight (NCT07784270)(2026)Phase 3, recruiting, 1,500 participants planned. Intervention listed as Drug: Lenbelintide, other name AZD6234, from the record version submitted October 26, 2026.
- ClinicalTrials.gov, SELENE 1, AZD6234 in obesity or overweight without type 2 diabetes (NCT07784725)(2026)Phase 3, recruiting, 2,500 participants planned. Intervention listed as Drug: Lenbelintide, other name AZD6234, from the record version submitted October 28, 2026.
- WHO Drug Information, Proposed INN List 133(2025)Lenbelintide (lenbelintidum) published as a proposed INN, July 11, 2025, described as a dual amylin/calcitonin receptor agonist for obesity; CAS 2793341-99-6.
- WHO Drug Information, Recommended INN List 95(2026)Lenbelintide published as a recommended INN, March 30, 2026.
- Hornigold et al., EASD 2024 abstract 707, Characterisation of AZD6234 in rodent models of weight loss and aversion (Diabetologia 67, Suppl 1)(2024)Conference abstract, session SO 057. Reports AMY3R to CTR relative potency of 1.6 (human) and 0.9 (rat), described as matching pramlintide and mimicking endogenous amylin; n>14 is the experiment count, not a fold figure. Rat data: dose-dependent food-intake and body-weight reduction, fat-mass loss with lean mass preserved, no added taste aversion on top of semaglutide.
- AstraZeneca, Meet the Management: Weight Management investor presentation, November 4, 2024(2024)Company slides. Describes AZD6234 as a selective amylin agonist and a novel amylin receptor selective agonist peptide; gives no fold-selectivity figure, no potency values and no DACRA comparison.
- Alhazmi and le Roux, Amylin analogs: the next major class of weight loss therapy, Diabetes, Obesity and Metabolism(2026)Peer-reviewed review, read via a reproduction of the PDF. Classes AZD6234 as a selective amylin receptor agonist targeting AMY3R, citing the EASD 2024 abstract; gives no fold-selectivity figure.
Beyond these, 18 records are indexed for this compound. Browse the records
